Ampyrimine is a diuretic agent.

Inicarone is benzofuryl derivative with potent antifibrinolytic activity.

Bepafant (also known as WEB-2170), an inverse agonist of platelet-activating factor receptor that has been preclinical studied in asthma, Ischemic heart disorder and in reperfusion injury after orthotopic liver transplantation. However, these studies were discontinued. Besides, several experiments have shown that bepafant induced apoptosis in human acute myelogenous leukemia and thus could be the powerful antileukemic agent.

Sitalidone (HOE-708) is a potent thiazide-like diuretic and antihypertensive drug.

Coumetarol is an anticoagulant, acting as a vitamin K antagonist, developed by the Dutch pharmaceutical company N.V. Amsterdamsche Chininefabriek. Coumetarol exhibited activity in rat models of venous and arterial thrombosis, where it was administered orally in a dose of 25 mg/kg twice daily.

Sulfonamide derivative Disulfamide was developed as diuretic agent.

Bemetizide was used as a thiazidediuretic. The information about the nowadays application of this drug is not available.

Beciparcil, an antithrombotic drug, that was studied against thrombosis, however, further investigations were discontinued in 1997.

Modipafant is a dihydropyridine derivative patented by American multinational pharmaceutical corporation Pfizer Ltd. as platelet-activating factor antagonist for bronchoconstriction and asthma treatment. Platelet-activating factor, proposed as an important inflammatory mediator in asthma, reproduces several of the features of asthma, such as microvascular leakage, mucus secretion, bronchoconstriction, and possibly increased airway responsiveness. Unfortunately, in clinical trials, Modipafant failed to demonstrate superior efficacy compared to placebo.

Quincarbate is a quinoline derivative patented by N. V. Philips' Gloeilampenfabrieken as diuretic. At 12.5 mg/kg orally in rats Quincarbate increased urine excretion by 130%.